Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Market Status
  5. Marketed
  6. Revised Labelling

Revised Labelling

Evaluate

Thumbnail
May 22, 2023

Intercept’s Nash exit feels inevitable

Thumbnail
May 17, 2023

Astra knocks another hole in J&J's Mariposa plan

Article image
Vantage logo
May 02, 2023

The sellside hacks back Lynparza’s prostate opportunity

The writing had been on the wall for Parp inhibitors in first-line prostate cancer, and last week’s US panel showed no mercy.

Article image
Vantage logo
March 27, 2023

Natalee delivers Novartis a much-needed win

Article image
Vantage logo
March 23, 2023

Dupixent pushes towards a big new use

Article image
Vantage logo
March 10, 2023

Polivy adcom: no overall survival, no problem

A US adcom surprisingly backs Polivy’s front-line use, and blockbuster sales could follow.

Article image
Vantage logo
March 09, 2023

Roche is losing its perioperative lung cancer lead

Article image
Vantage logo
January 27, 2023

What Abecma does Carvykti might do better

Article image
Vantage logo
January 25, 2023

Immuno-oncology goes subcutaneous

A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.

Article image
Vantage logo
November 23, 2022

Ash 2022 preview – Brukinsa has the edge over Calquence

Brukinsa’s head-to-head victory over Imbruvica is confirmed, and the Beigene BTK inhibitor looks better than Calquence too.

Article image
Vantage logo
November 07, 2022

Time for GSK to stop dreaming about Blenrep

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up